These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26238184)

  • 1. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
    Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
    Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cells and their vascular niche: Do they benefit from each other?
    Ping YF; Zhang X; Bian XW
    Cancer Lett; 2016 Oct; 380(2):561-567. PubMed ID: 25979233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial foreword special issue: "Angiogenesis-convergent or divergent, that is the question: Research toward targeted strategies in oncology".
    Cai J
    Cancer Lett; 2016 Oct; 380(2):523-524. PubMed ID: 27032878
    [No Abstract]   [Full Text] [Related]  

  • 7. Redundant angiogenic signaling and tumor drug resistance.
    Gacche RN; Assaraf YG
    Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
    Maes H; Olmeda D; Soengas MS; Agostinis P
    FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholamines regulate tumor angiogenesis.
    Chakroborty D; Sarkar C; Basu B; Dasgupta PS; Basu S
    Cancer Res; 2009 May; 69(9):3727-30. PubMed ID: 19383906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current insights into the association of Nestin with tumor angiogenesis.
    Onisim A; Achimas-Cadariu A; Vlad C; Kubelac P; Achimas-Cadariu P
    J BUON; 2015; 20(3):699-706. PubMed ID: 26214620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why haven't we cured cancer?
    Harding E
    Lancet Oncol; 2017 Jul; 18(7):861-862. PubMed ID: 28677566
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.
    Craven KE; Gore J; Korc M
    Cancer Lett; 2016 Oct; 381(1):201-10. PubMed ID: 26723874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies.
    Ye L; Jiang WG
    Cancer Lett; 2016 Oct; 380(2):586-597. PubMed ID: 26639195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
    Cao Y; Zhong W; Sun Y
    Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
    Welti J; Loges S; Dimmeler S; Carmeliet P
    J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Angiogenesis agents.
    Marcinkiewicz C
    Curr Pharm Des; 2007; 13(35):3543-4. PubMed ID: 18220790
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular disrupting agents in cancer therapy.
    Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
    Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy.
    Jiang L; Li N
    Angiogenesis; 2020 Nov; 23(4):515-529. PubMed ID: 32451774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.